Newsfeeds Archive - Page 2 of 167

1 minute read

Roivant Reports Chronic Period Data For RVT-3101 From TUSCANY-2 Phase 2b Study In Ulcerative Colitis; Phase 3 Once-Monthly Subcutaneous Dose Resulted In Improved Clinical Remission

June 22, 7:35 AM

This is the first-ever long-duration data reported for an anti-TL1A antibody At the expected Phase 3 once-monthly subcutaneous dose in the overall population, RVT-3101 treatment resulted in improved Clinical

ROIV

2 minute read

Amarin Announces Vascepa Approved To Reduce Cardiovascular Risk In Kingdom Of Saudi Arabia

By Bill Haddad

June 21, 9:05 AM

-- VASCEPA® Approved in KSA To Reduce the Risk of Cardiovascular (CV) Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT--

AMRN

1 minute read

Here’s Why Farfetch Shares Are Rallying After Hours

By Bill Haddad

May 18, 5:11 PM

Farfetch (NYSE: FTCH) shares are trading higher after the company reported better-than-expected Q1 results, with EPS and sales beating consensus estimates.

FTCH

1 minute read

‘Japan to subsidize half of costs for lithium and key mineral projects’ -Nikkei

By Bill Haddad

April 22, 3:53 PM

https://asia.nikkei.com/Economy/Japan-to-subsidize-half-of-costs-for-lithium-and-key-mineral-projects#:~:text=Japan%20to%20subsidize%20half%20of%20costs%20for%20lithium%20and%20key%20mineral%20projects,-Push%20to%20reduc https://asia.nikkei.com/Economy/Japan-to-subsidize-half-of-costs-for-lithium-and-key-mineral-projects#:~:text=Japan%20to%20subsidize%20half%20of%20costs%20for%20lithium%20and%20key%20mineral%20projects,-Push%20to%20reduce&text=TOKYO%20%2D%2D%20The%20Ministry%20of,Japanese%20companies%2C%20Nikkei%20has%20learned.

EWJ

1 minute read

ImmunoPrecise’s Subsidiary Talem Enters Exclusive Research Collaboration And License Option Agreement With Astellas

By Bill Haddad

March 30, 8:05 AM

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("ImmunoPrecise" or "IPA" or the "Company") an AI-driven biotherapeutic research and technology company today announced a research collaboration

IPA

1 minute read

Xeris Biopharma Announces Research Evaluation Collaboration And Option Agreement With Regeneron For XeriJect

By Bill Haddad

March 30, 7:18 AM

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapeutic areas,

XERS

1 minute read